- Home
- BFAC vs ATOS Comparison
BFAC vs ATOS Comparison
Compare BFAC & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFAC
- ATOS
- Stock Information
- Founded
- BFAC 2021
- ATOS 2009
- Country
- BFAC United States
- ATOS United States
- Employees
- BFAC N/A
- ATOS N/A
- Industry
- BFAC Blank Checks
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- BFAC Finance
- ATOS Health Care
- Exchange
- BFAC Nasdaq
- ATOS Nasdaq
- Market Cap
- BFAC 152.7M
- ATOS 174.8M
- IPO Year
- BFAC 2021
- ATOS 2012
- Fundamental
- Price
- BFAC $11.12
- ATOS $1.28
- Analyst Decision
- BFAC
- ATOS Strong Buy
- Analyst Count
- BFAC 0
- ATOS 3
- Target Price
- BFAC N/A
- ATOS $6.75
- AVG Volume (30 Days)
- BFAC 4.9K
- ATOS 658.8K
- Earning Date
- BFAC 01-01-0001
- ATOS 11-12-2024
- Dividend Yield
- BFAC N/A
- ATOS N/A
- EPS Growth
- BFAC 140.63
- ATOS N/A
- EPS
- BFAC 0.60
- ATOS N/A
- Revenue
- BFAC N/A
- ATOS N/A
- Revenue This Year
- BFAC N/A
- ATOS N/A
- Revenue Next Year
- BFAC N/A
- ATOS N/A
- P/E Ratio
- BFAC $18.56
- ATOS N/A
- Revenue Growth
- BFAC N/A
- ATOS N/A
- 52 Week Low
- BFAC $10.78
- ATOS $0.65
- 52 Week High
- BFAC $11.55
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- BFAC 52.05
- ATOS 37.45
- Support Level
- BFAC $11.13
- ATOS $1.36
- Resistance Level
- BFAC $11.14
- ATOS $1.66
- Average True Range (ATR)
- BFAC 0.00
- ATOS 0.08
- MACD
- BFAC -0.01
- ATOS -0.02
- Stochastic Oscillator
- BFAC 62.50
- ATOS 0.00
About BFAC Battery Future Acquisition Corp.
Battery Future Acquisition Corp is a blank check company.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.